Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

755
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
755
Menopause01:28

Menopause

5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.9K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.9K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

993
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
993
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

824
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
824

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological Factors Domain Is a Necessity for the Future <i>DSM</i>.

The American journal of psychiatry·2026
Same author

Attitudes towards conceptual and philosophical issues in psychiatry and psychiatric education: A survey of US and UK trainees.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2026
Same author

An Anterior Cingulate Cortex Neuronal Ensemble Controls Contextual Opioid Analgesic Tolerance.

bioRxiv : the preprint server for biology·2025
Same author

The Rumpelstiltskin effect: therapeutic repercussions of clinical diagnosis.

BJPsych bulletin·2025
Same author

Hierarchical, Interactive, and Dynamic Predictive Capacity of Current Biological, Psychological, Social, and Environmental Measurements in Depression, Anxiety, ADHD, and Social Quality across the Lifespan.

Research square·2025
Same author

Measured thoracic gas volume using the bod pod air displacement plethysmography system versus three predictions.

European journal of applied physiology·2025

Related Experiment Video

Updated: Mar 11, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Flibanserin and its discontents.

Awais Aftab1, Cheryl Chen2, Jacob McBride3

  • 1Department of Psychiatry, Case Western Reserve University/University Hospitals Cleveland Medical Center, 10524 Euclid Avenue, 8th Floor, Cleveland, OH, 44106, USA. awaisaftab@gmail.com.

Archives of Women'S Mental Health
|November 19, 2016
PubMed
Summary

Flibanserin (Addyi) is a medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. While modestly effective and safe, its approval and use remain controversial, sparking debate on diagnosis and treatment.

Keywords:
EthicsFemale sexualityFlibanserinHypoactive sexual desire disorderWomen’s mental health

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.7K

Related Experiment Videos

Last Updated: Mar 11, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.7K

Area of Science:

  • Pharmacology
  • Women's Health
  • Psychiatry

Background:

  • Hypoactive sexual desire disorder (HSDD) affects premenopausal women.
  • Flibanserin (Addyi) received FDA approval in August 2015 for HSDD treatment.
  • The drug's approval and efficacy have been subjects of significant controversy.

Purpose of the Study:

  • To review and discuss controversies surrounding flibanserin.
  • To examine the safety and efficacy of flibanserin.
  • To explore philosophical considerations of HSDD diagnosis and treatment.

Main Methods:

  • Literature review of flibanserin's approval and clinical trials.
  • Analysis of safety and efficacy data.
  • Discussion of philosophical viewpoints on HSDD and libido treatment.

Main Results:

  • Flibanserin is considered modestly effective for HSDD.
  • The drug is deemed reasonably safe for its intended use.
  • Clinical trial validity and HSDD diagnosis remain debated topics.

Conclusions:

  • Flibanserin offers a pharmacological option for HSDD.
  • Ongoing debate exists regarding HSDD diagnosis and treatment.
  • Differing philosophical perspectives contribute to the complexity of low libido treatment.